Artificial Intelligence technology is being developed and combined with our present technologies to create new unique possibilities for image processing and future innovative products.
We are continuing to enhance our tools for remote communication and customer support. These tools and communication formats will also be valuable post-pandemic. The present year will hopefully offer a gradual return to an environment where both digital and physical meetings and interactions are normal options. We truly appreciate all the joint endeavors to prevent spread of the virus, and are determined to further our progress in business projects. We greatly look forward to meet our customers and partners face to face as soon as possible.
ContextVision AB: Ex dividend SEK 0,15 todayThe shares in ContextVision AB will be traded ex dividend SEK 0,15 as from today, 8 May 2023. newsweb.oslobors.no
ContextVision AB - Key information relating payment of cash dividend * CorrectionKey information relating payment of cash dividend * Correction
ContextVision debuts the latest innovation in Ultrasound: Rivent 3DContextVision announces Rivent 3D, an evolution in ultrasound medical imaging technology. Rivent 3D is based on the benefits of volumetric processi...
Installed in more than 300K systems worldwide
Already a world leader in image enhancement, ContextVision is now taking its medical analysis know-how into a new field. The near future will see the launch of our first Digital Pathology product, INIFY® Prostate, based on the latest breakthroughs in AI and deep learning.
ContextVision’s primary strength is our motivated and talented workforce. We want to add to that strength by employing talented individuals who are willing to work for a leading company dedicated to medical imaging and innovative technologies. In return, we will encourage you to develop and manage your career with us, in a stimulating and international environment.
Welcome to ContextVision!